TAUG Appoints Colorado-based Orthopedic Surgeon, Dr. Craig Loucks, as Member of the Company's Advisory Board
June 23 2021 - 9:34AM
InvestorsHub NewsWire
NEW YORK, NY -- June 23, 2021 -- InvestorsHub NewsWire -- Tauriga
Sciences, Inc. (OTCQB: TAUG)
(“Tauriga” or the “Company”), a New York based diversified Life
Sciences Company, today announced the appointment of Dr. Craig
Loucks (“Dr. Loucks”) as a member of the Company’s Advisory
Board. Dr. Loucks is an accomplished orthopedic surgeon,
based in Englewood, Colorado. Dr. Loucks is a strong
believer in Cannabidiol (“CBD”) based products and has pre-ordered
the Company’s enhanced 25mg CBD and CBG infused Tauri-Gum™
products. Dr. Loucks will mainly assist the Company in
generating Tauri-Gum™ product sales, from both Medical Practices
and Dispensaries. He will also provide his expertise to
the Company, with respect to its ongoing Pharmaceutical development
efforts.
Link to Personal Bio – Craig Loucks, MD:
Link: https://www.peakorthopedics.com/craig-loucks-peak-orthopedics-spine.html
Dr. Craig Loucks stated, “I am both pleased and excited to join
Tauriga Sciences, Inc. as a member of the Company’s advisory
board. The Tauri-Gum™ product line is of outstanding
quality and incorporates sublingual absorption delivery
method. There is a significant opportunity for Tauriga
to market this product line to both medical practices and
dispensaries throughout the state of Colorado. I look
forward to working closely with Tauriga’s management team as well
as its Chief Medical Officer.”
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG)
is a revenue generating, diversified life sciences company, engaged
in several major business activities and
initiatives. The company manufactures and distributes
several proprietary retail products and product lines, mainly
focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles
market segment. The main product line, branded as
Tauri-Gum™, consists of a proprietary supplement chewing gum that
is Kosher certified, Halal certified, and Vegan Formulated (CBD
Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG
Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant), (Vitamin C
+ Zinc Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused
Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused
Tauri-Gum™ Flavor: Golden Raspberry). The Company’s
commercialization strategy consists of a broad array of retail
customers, distributors, and a fast-growing E-Commerce business
segment (E-Commerce website: www.taurigum.com). Please visit
our corporate website, for additional information, as well as
inquiries, at http://www.tauriga.com
Complementary to the Company’s retail business, is its ongoing
Pharmaceutical Development initiative. This relates to the
development of a proposed Pharmaceutical grade version of
Tauri-Gum™, for nausea regulation (specifically designed for the
following indication: Patients Subjected to Ongoing Chemotherapy
Treatment). On March 22, 2021, the Company announced that it had
Converted its U.S. Provisional Patent Application (filed on March
17, 2020) into a U.S. Non-Provisional Patent
Application. The Patent, filed with the U.S.P.T.O. is
Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND
METHODS OF TREATMENT”. On December 18, 2020 the Company
disclosed that it had entered into a Master Services Agreement with
CSTI to lead the Company's clinical development efforts.
The Company is headquartered in Wappingers Falls, New
York. In addition, the Company operates two full time
E-Commerce fulfillment centers: one located in Montgomery, Texas
and the other in Brooklyn, New York.
DISCLAIMER -- Forward-Looking Statements
This press release contains certain “forward-looking statements”
as defined by the Private Securities Litigation Reform Act of 1995
which represent management’s beliefs and assumptions concerning
future events. These forward-looking statements are often indicated
by using words such as “may,” “will,” “expects,” “anticipates,”
believes, “hopes,” “believes,” or plans, and may include statements
regarding corporate objectives as well as the attainment of certain
corporate goals and milestones. Forward-looking statements are
based on present circumstances and on management’s present beliefs
with respect to events that have not occurred, that may not occur,
or that may occur with different consequences or timing than those
now assumed or anticipated. Actual results may differ materially
from those expressed in forward looking statements due
to known and unknown risks and uncertainties, such as are not
guarantees of general economic and business conditions, the ability
to successfully develop and market products, consumer and business
consumption habits, the ability to consummate successful
acquisition and licensing transactions, fluctuations in exchange
rates, and other factors over which Tauriga has little or no
control. Many of these risks and uncertainties are discussed in
greater detail in the “Risk Factors” section of Tauriga’s Form 10-K
and other periodic filings made from time to time with the
Securities and Exchange Commission. Such forward-looking statements
are made only as of the date of this release, and Tauriga assumes
no obligation to update forward-looking statements to reflect
subsequent events or circumstances. You should not place undue
reliance on these forward-looking statements.
Contact:
Tauriga Sciences, Inc.
4 Nancy Court, Suite 4
Wappingers Falls, NY 12590
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Company Instagram: @taurigum
Personal Instagram: @sethsms47
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com